E. coli O157:H7 bacteriophage and uses thereof
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
MemberIntralytixIntralytixIntralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Intralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Publication Number
US-7625741-B2
Publication Date
2009-12-01
Expiration Date
Abstract
The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli O157:H7, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli O157:H7 in various settings.
Core Innovation
The invention describes isolated E. coli O157:H7 bacteriophages ECML-117 (ATCC PTA-7950) and ECML-134 (ATCC PTA-7949), and variants thereof. The bacteriophage compositions are substantially pure and are defined by phenotypic characteristics and lytic activity against E. coli O157:H7 strains.
The invention characterizes the isolated bacteriophages and their relationships using RFLP profiles and restriction fragment length polymorphism, including phenotypic/genotypic equivalence criteria. It describes strong lytic specificity for E. coli O157:H7 while largely not lysing non-target E. coli and several other bacterial species.
The invention presents uses of the isolated ECML-117 and ECML-134 bacteriophages and their variants in food safety and microbiological applications. It describes prevention or reduction of colonization and spoilage via phage-mediated lysis, environmental decontamination including biofilm control, and detection and typing of viable target bacteria using phage-mediated lysis with reporter and/or ATP readouts.
Claims Coverage
The partial content provides two independent claims: one directed to a substantially pure bacteriophage composition with defined isolates and equivalent variants, and another directed to a method for reducing the incidence of foodborne illnesses caused by E. coli O157:H7 using the defined bacteriophage composition.
Substantially pure bacteriophage composition with defined ECML-117 or ECML-134 isolates and equivalent variants
A substantially pure bacteriophage composition comprising the isolated bacteriophages ECML-117 or ECML-134 deposited under ATCC accession Nos. PTA-7950 and PTA-7949 and variants thereof, wherein said variants have the same phenotypic characteristics of said bacteriophage, and wherein said bacteriophage and variants thereof have the same lytic activity against E. coli O157:H7 strains.
Reduction of foodborne illness incidence by contacting food products with ECML-117 or ECML-134 bacteriophage composition
A method for the reduction of the incidence of foodborne illnesses caused by E. coli O157:H7 strains, comprising contacting a food product or products with a microbial growth inhibiting effective amount of a bacteriophage composition comprising the isolated bacteriophages ECML-117 or ECML-134 deposited under ATCC accession Nos. PTA-7950 and PTA-7949, and variants thereof, wherein said variants have the same phenotypic characteristics of said bacteriophage, and wherein said bacteriophage and variants thereof have the same lytic activity against E. coli O157:H7 strains.
Across the independent claims, the core coverage is a substantially pure composition defined by ECML-117/ECML-134 isolates at specific ATCC accessions with variants retaining the same phenotypic characteristics and lytic activity against E. coli O157:H7 strains, and use of that composition to reduce the incidence of E. coli O157:H7 foodborne illnesses by contacting food products with a microbial growth inhibiting effective amount of the specified bacteriophage composition.
Stated Advantages
Strong lytic specificity for E. coli O157:H7 while largely not lysing non-target E. coli and several other bacterial species.
Prevention or reduction of colonization and spoilage using phage-mediated lysis.
Environmental decontamination, including biofilm control.
Detection and typing of viable target bacteria using phage-mediated lysis with reporter/ATP readouts.
Prevention and treatment of human and animal diseases, including via recombinant reporter phages and phage-lysate vaccines/bacterins.
Documented Applications
Prevention or reduction of colonization and spoilage in food contexts using bacteriophages ECML-117 and ECML-134 and variants.
Environmental decontamination, including biofilm control.
Detection and typing of viable E. coli O157:H7 using phage-mediated lysis with reporter/ATP readouts.
Prevention and treatment of human and animal diseases, including via recombinant reporter phages and phage-lysate vaccines/bacterins.
Interested in licensing this patent?